SCM
Superstring Capital Management Portfolio holdings
AUM
$80.3M
This Quarter Return
+1.98%
1 Year Return
+68.23%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$83.8M
AUM Growth
+$83.8M
(-26%)
Cap. Flow
-$22.3M
Cap. Flow
% of AUM
-26.59%
Top 10 Holdings %
Top 10 Hldgs %
66.17%
Holding
52
New
13
Increased
7
Reduced
9
Closed
18
Top Buys
| 1 |
VRNA
Verona Pharma
VRNA
|
$6.15M |
| 2 |
Pfizer
PFE
|
$4.97M |
| 3 |
Travere Therapeutics
TVTX
|
$4.26M |
| 4 |
Legend Biotech
LEGN
|
$3.08M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
$2.39M |
Top Sells
| 1 |
NovoCure
NVCR
|
$8.55M |
| 2 |
Structure Therapeutics
GPCR
|
$5.88M |
| 3 |
IDEAYA Biosciences
IDYA
|
$5.84M |
| 4 |
Oric Pharmaceuticals
ORIC
|
$4.25M |
| 5 |
Zai Lab
ZLAB
|
$3.93M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Zai Lab
ZLAB
$3.68B
| $10.7M | 12.68% | 294,947 -108,683 | -27% | -$3.93M |
|
2
BridgeBio Pharma
BBIO
$9.89B
| $6.36M | 7.56% | 183,922 -78,219 | -30% | -$2.7M |
|
|
VRNA
3
Verona Pharma
VRNA
$9.16B
| $6.15M | 7.31% | +96,821 | New | +$6.15M |
|
|
4
Legend Biotech
LEGN
$6.41B
| $5.44M | 6.48% | 160,442 +90,848 | +131% | +$3.08M |
|
|
5
Pfizer
PFE
$141B
| $4.97M | 5.91% | +196,164 | New | +$4.97M |
|
6
UroGen Pharma
URGN
$900M
| $4.69M | 5.57% | 423,632 +122,426 | +41% | +$1.35M |
|
7
Cogent Biosciences
COGT
$1.69B
| $4.64M | 5.52% | 774,721 -136,144 | -15% | -$816K |
|
|
8
Oric Pharmaceuticals
ORIC
$994M
| $4.57M | 5.44% | 819,194 -761,551 | -48% | -$4.25M |
|
|
9
Travere Therapeutics
TVTX
$1.56B
| $4.26M | 5.06% | +237,487 | New | +$4.26M |
|
10
Terns Pharmaceuticals
TERN
$609M
| $3.75M | 4.46% | 1,357,153 -663,409 | -33% | -$1.83M |
|
11
Cytokinetics
CYTK
$4.23B
| $2.93M | 3.49% | 72,992 -56,397 | -44% | -$2.27M |
|
12
Savara
SVRA
$567M
| $2.68M | 3.18% | 966,203 +457,865 | +90% | +$1.27M |
|
13
Summit Therapeutics
SMMT
$17.6B
| $2.55M | 3.03% | 132,019 -32,545 | -20% | -$628K |
|
|
SWTX
14
DELISTED
SpringWorks Therapeutics
SWTX
| $2.39M | 2.85% | +54,216 | New | +$2.39M |
|
15
Capricor Therapeutics
CAPR
$287M
| $2.29M | 2.72% | 241,192 +185,963 | +337% | +$1.76M |
|
16
Verastem
VSTM
$569M
| $2.03M | 2.41% | 336,363 +126,474 | +60% | +$763K |
|
17
Protara Therapeutics
TARA
$120M
| $1.53M | 1.82% | 360,000 | – | – |
|
18
Crinetics Pharmaceuticals
CRNX
$2.92B
| $1.46M | 1.74% | +43,613 | New | +$1.46M |
|
19
Soleno Therapeutics
SLNO
$3.6B
| $1.38M | 1.64% | +19,332 | New | +$1.38M |
|
20
Madrigal Pharmaceuticals
MDGL
$9.76B
| $1.26M | 1.5% | 3,815 +2,686 | +238% | +$890K |
|
21
MoonLake Immunotherapeutics
MLTX
$3.54B
| $1.26M | 1.49% | +32,145 | New | +$1.26M |
|
22
Taysha Gene Therapies
TSHA
$797M
| $1.05M | 1.25% | +755,599 | New | +$1.05M |
|
|
TECX
23
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $899K | 1.07% | +50,746 | New | +$899K |
|
|
ZBIO
24
Zenas BioPharma, Inc. Common Stock
ZBIO
$674M
| $882K | 1.05% | 111,605 | – | – |
|
25
89bio
ETNB
$1.34B
| $794K | 0.94% | 109,156 -23,826 | -18% | -$173K |
|